Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- How Will Distribution Practice Be Improved Following Pricing System Reform? - Part 2 (2)
May 24, 2010
- Humira Achieves Clinical Remission Rate of 17.7% in 24 Weeks: PMS Data
May 24, 2010
- Janssen, Takeda to Copromote VELCADE in Japan
May 24, 2010
- Equa Can Become 1st-Choice DPP-4 Inhibitor: Prof. Kadowaki
May 24, 2010
- Santen Launches Tafluprost in South Korea
May 24, 2010
- Proper Use of Topical Steroids Should Be Promoted: Prof. Horio
May 24, 2010
- Daiichi Sankyo Voluntarily Recalls Amplit Tablets 25 mg
May 24, 2010
- Erbitux Makes Hepatic Metastasis of Colon Cancer Curable: Prof. Sugihara
May 24, 2010
- Need for Biosimilars Highlighted at CPhI 2010 Panel Discussion
May 24, 2010
- Cervarix Shows Immunological Responses Significantly Higher Than Gardasil: Dr Einstein
May 24, 2010
- Joji Nakayama to Be Appointed President of Daiichi Sankyo
May 24, 2010
- Teva-Kowa to Integrate Taisho Pharm's Marketing Division in July
May 24, 2010
- Cervarix Offers “Excellent Protection”for Japanese Women As Well: Prof. Konno
May 24, 2010
- Takeda: Sales Down 4.7% Due to Patent Expiration for Lansoprazole in the US
May 24, 2010
- Kissei to Launch Japan's 1st EPO Biosimilar
May 24, 2010
- Astellas to Acquire OSI Pharmaceuticals
May 24, 2010
- Major New Entrants in Generics Market, Emergence of AGs (1)
May 24, 2010
- Astellas: Profits Down >25% Due to Patent Expiration for Prograf
May 24, 2010
- Major New Entrants in Generics Market, Emergence of AGs (2)
May 24, 2010
- Daiichi Sankyo: Sales Up 13.1% Driven by Olmesartan, Ranbaxy
May 24, 2010
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…